<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607880</url>
  </required_header>
  <id_info>
    <org_study_id>P30CA015083</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>52-04</secondary_id>
    <nct_id>NCT00607880</nct_id>
  </id_info>
  <brief_title>Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy</brief_title>
  <official_title>A Prospective Randomized Study of the Vortex® Implantable Access Port Versus the BardPort™ Implantable Port in Cancer Patients Receiving Adjuvant Intravenous Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs through an implanted port reduces the need for multiple
      needle sticks. It is not yet known whether one type of port is more effective than another in
      reducing infections and other side effects associated with long-term port use.

      PURPOSE: This randomized clinical trial is comparing two types of ports in patients with
      cancer receiving intravenous chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the rate of port failure, defined as the occurrence of port malfunction or
           port infection within 12 months after port insertion, in patients with cancer requiring
           long-term adjuvant intravenous chemotherapy undergoing insertion of a newly designed,
           FDA-approved Vortex® implantable vascular access port vs a conventional vascular access
           port.

      Secondary

        -  To compare the rate of port malfunction or port infection at 6 and 12 months after port
           insertion.

        -  To compare the rate of central vein thrombosis at 6 and 12 months after port insertion.

        -  To compare the rate of port removal for any reason other than infection or occlusion at
           6 and 12 months after port insertion.

        -  To compare the rate of termination of use of the indwelling port at 6 and 12 months
           after port insertion.

        -  To compare the death from all causes.

        -  To compare the incidence of port-related interventions at 6 and 12 months after port
           insertion.

      OUTLINE: Patients are randomized to 1 of 2 intervention arms.

        -  Arm I: Patients undergo insertion of a conventional vascular access port. Patients then
           receive standard chemotherapy.

        -  Arm II : Patients undergo insertion of the Vortex® implantable vascular access port.
           Patients then receive standard chemotherapy.

      All episodes of access to the port are documented for 12 months after port insertion.
      Information including the reason for port access and difficulty in access is collected.
      Complications, such as occlusion and infection, implant duration, and incidence of
      port-related interventions are assessed at 6 and 12 months after port insertion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Port Failure Within 12 Months of Port Insertion</measure>
    <time_frame>Up to 12 months from port insertion</time_frame>
    <description>We report the proportion of patients in each treatment group who have some degree of port failure. Port failure is defined as the composite outcome of port malfunction due to partial or total occlusion and any infection related to the port, within 12 months of port insertion. The percentages reported here are the number of patients that had reported a port failure within 12 months out of the number of patients with port failure within 12 months plus the number of patients that were followed 12 months without port failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death From All Causes</measure>
    <time_frame>Up to 12 months after port insertion</time_frame>
    <description>Number of patients that died during treatment due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Port Removal for Any Reason Other Than Infection or Occlusion Within 12 Months After Port Insertion</measure>
    <time_frame>Up to 12 months after port insertion</time_frame>
    <description>We report the number of patients that terminated use of port due to any reason other than infection or occlusion within 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Termination of Use of the Indwelling Port at 12 Months After Port Insertion</measure>
    <time_frame>Up to 12 months after port insertion</time_frame>
    <description>The number of patients that discontinued use of inserted port for any reason at the 12 month timepoint.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Vascular Access Device Complications</condition>
  <arm_group>
    <arm_group_label>Standard Port</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortex Implantable Access Port</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vascular access device placement</intervention_name>
    <arm_group_label>Standard Port</arm_group_label>
    <arm_group_label>Vortex Implantable Access Port</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of malignancy requiring intravenous chemotherapy for ≥ 6 months

               -  Must undergo entire course of chemotherapy at the Mayo Clinic in Jacksonville,
                  unless the outside treating institution agrees to submit the research data sheet
                  to Mayo Clinic

          -  Scheduled time frame for regular use of the vascular access port ≥ 3 months after port
             insertion

        PATIENT CHARACTERISTICS:

          -  Life expectancy ≥ 6 months

          -  No active skin condition implicating an elevated risk of local or systemic infectious
             or non-infectious complications, including any of the following:

               -  Current skin infection

               -  Cutaneous lymphoma

               -  Auto-immune disorders

               -  Active vasculitis

               -  Connective tissue diseases

          -  No known active infection requiring antibiotic therapy at the time of port
             implantation

               -  Patients without an active infection who are on chronic antibiotic suppressive
                  therapy are eligible

          -  No concurrent illness requiring chronic anticoagulation

               -  Patients who develop other comorbidities requiring chronic anticoagulation during
                  the study period are eligible

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert G. Hakaim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>April 9, 2014</results_first_submitted>
  <results_first_submitted_qc>April 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2014</results_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vascular access device complications</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients considered for port implantation for intravenous chemotherapy were consulted and evaluated for port implantation. This evaluation was not study specific. If the implantation of a port system was feasible, the patient fulfilled inclusion criteria and the patient consented to the study, then they were randomly assigned a treatment port.</recruitment_details>
      <pre_assignment_details>One patient in the Standard Access Port group was unable to have the port placed due to chronic left internal jugular occlusion and was excluded from the analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Access Port</title>
          <description>Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.</description>
        </group>
        <group group_id="P2">
          <title>Vortex Implantable Access Port</title>
          <description>Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable to place port due to occlusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 100 patients accrued to participate in this study were included in the baseline population analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard Access Port</title>
          <description>Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.</description>
        </group>
        <group group_id="B2">
          <title>Vortex Implantable Access Port</title>
          <description>Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="35" upper_limit="93"/>
                    <measurement group_id="B2" value="64" lower_limit="31" upper_limit="81"/>
                    <measurement group_id="B3" value="65" lower_limit="31" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Port Failure Within 12 Months of Port Insertion</title>
        <description>We report the proportion of patients in each treatment group who have some degree of port failure. Port failure is defined as the composite outcome of port malfunction due to partial or total occlusion and any infection related to the port, within 12 months of port insertion. The percentages reported here are the number of patients that had reported a port failure within 12 months out of the number of patients with port failure within 12 months plus the number of patients that were followed 12 months without port failure.</description>
        <time_frame>Up to 12 months from port insertion</time_frame>
        <population>Patients with port failure within 12 months and patients that were followed 12 months without port failure were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Access Port</title>
            <description>Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Vortex Implantable Access Port</title>
            <description>Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Port Failure Within 12 Months of Port Insertion</title>
          <description>We report the proportion of patients in each treatment group who have some degree of port failure. Port failure is defined as the composite outcome of port malfunction due to partial or total occlusion and any infection related to the port, within 12 months of port insertion. The percentages reported here are the number of patients that had reported a port failure within 12 months out of the number of patients with port failure within 12 months plus the number of patients that were followed 12 months without port failure.</description>
          <population>Patients with port failure within 12 months and patients that were followed 12 months without port failure were included in this analysis.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="3.2" upper_limit="29.0"/>
                    <measurement group_id="O2" value="13.8" lower_limit="1.2" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death From All Causes</title>
        <description>Number of patients that died during treatment due to any cause.</description>
        <time_frame>Up to 12 months after port insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Access Port</title>
            <description>Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Vortex Implantable Access Port</title>
            <description>Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Death From All Causes</title>
          <description>Number of patients that died during treatment due to any cause.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Port Removal for Any Reason Other Than Infection or Occlusion Within 12 Months After Port Insertion</title>
        <description>We report the number of patients that terminated use of port due to any reason other than infection or occlusion within 12 months.</description>
        <time_frame>Up to 12 months after port insertion</time_frame>
        <population>All patients accrued to this study that had their port removed within12 months for any reason other than infection/occlusion were included in this analysis. 28 patients using the Standard Access Port and 30 patients using the Vortex Implantable Access Port had port removal prior to 12 months due to reasons other than infection or occlusion..</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Access Port</title>
            <description>Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Vortex Implantable Access Port</title>
            <description>Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Port Removal for Any Reason Other Than Infection or Occlusion Within 12 Months After Port Insertion</title>
          <description>We report the number of patients that terminated use of port due to any reason other than infection or occlusion within 12 months.</description>
          <population>All patients accrued to this study that had their port removed within12 months for any reason other than infection/occlusion were included in this analysis. 28 patients using the Standard Access Port and 30 patients using the Vortex Implantable Access Port had port removal prior to 12 months due to reasons other than infection or occlusion..</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin Erosion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unhealed Incision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Moved/Transferred Care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Request</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Termination of Use of the Indwelling Port at 12 Months After Port Insertion</title>
        <description>The number of patients that discontinued use of inserted port for any reason at the 12 month timepoint.</description>
        <time_frame>Up to 12 months after port insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Access Port</title>
            <description>Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Vortex Implantable Access Port</title>
            <description>Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Termination of Use of the Indwelling Port at 12 Months After Port Insertion</title>
          <description>The number of patients that discontinued use of inserted port for any reason at the 12 month timepoint.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Access Port</title>
          <description>Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.</description>
        </group>
        <group group_id="E2">
          <title>Vortex Implantable Access Port</title>
          <description>Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with unknown ANC: Blood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <description>Vascular Access Complication, Port Occlusion</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert G. Hakaim, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>Hakaim.Albert@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

